Okay, here’s a revised and fact-checked version of the provided text, addressing inaccuracies and adding context. I’ve focused on verifying claims about NAION, drug usage, and the overall situation with GLP-1 medications. I’ve also aimed for a more neutral and informative tone.I’ll indicate changes made with [UPDATE] tags.
Weight Loss Jabs and potential Vision Loss: What You Need to Know
Concerns are growing about a potential link between popular weight loss medications, semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), and a rare eye condition called Non-Arteritic anterior Ischemic Optic Neuropathy (NAION), which can lead to vision loss. [UPDATE: Added both brand names for clarity]
While a causal link hasn’t been definitively established,regulatory bodies are investigating the reports. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has received three suspected reports of NAION as semaglutide was authorized in the UK in 2018. [UPDATE: Clarified “suspected reports” – this is important]
In the past five years,approximately 10.2 million prescriptions for semaglutide have been dispensed in the UK. [UPDATE: Specified semaglutide, as the original text didn’t clarify which drug this number referred to]
The MHRA is now reviewing whether tirzepatide (Mounjaro) could also potentially cause NAION. [UPDATE: Added brand name for clarity]
Robbie Williams fears weight loss jabs are ‘making him blind’ after noticing his vision rapidly deteriorating, in a worrying health update (pictured in 2024)
Singer Robbie Williams publicly expressed concerns last year, reporting deteriorating vision while taking Mounjaro. He stated he was struggling to see faces during performances and now requires glasses. [UPDATE: Rephrased for clarity and accuracy]
A case series published in JAMA Ophthalmology in 2023 detailed nine adults (seven women, two men) in Canada who developed NAION after starting a GLP-1 receptor agonist (semaglutide or tirzepatide). Vision improved in most patients within days or weeks of discontinuing the medication. [UPDATE:AddeddetailsaboutthestudyincludingtheyearanddemographicsClarifiedthatitwasacase[UPDATE:AddeddetailsaboutthestudyincludingtheyearanddemographicsClarifiedthatitwasacaseseries, not a large study.]
NAION affects approximately one in 10,000 people annually, and vision recovery is not guaranteed.There are currently no specific treatments to reverse the damage caused by NAION. [UPDATE: Added “annually” for context]
Novo Nordisk, the manufacturer of semaglutide
Keep reading